Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
STUDY IS CLOSED FOR ENROLLMENT
Inclusion Criteria:
Graves’ disease (GD) cohort 1
- ≥18 years of age
- TSH < 0.1 mIU/L
- RAI scan and uptake: symmetric bilateral and> LLN%
- Total T4 > 11.7 mcg/dL or total T3 > 200 ng/dL or Free T4 level: ≥1.7 ng/dL
- Newly diagnosed Graves’ disease OR previously diagnosed Graves’ disease with recurrent disease, and has been off anti-thyroid medication for at least 3 months
Painless thyroiditis (PT) cohort 2
- ≥18 years of age
- TSH < 0.1 mIU/L
- Thyroid uptake < 3%
- Total T4 > 11.7 mcg/dL or total T3 > 200 ng/dL or Free T4 level: ≥1.7 ng/dL
Subacute thyroiditis (SA) cohort 3
- ≥18 years of age
- TSH < 0.1 mIU/L
- Thyroid uptake < 3%
- Total T4 > 11.7 mcg/dL, or total T3 > 200 ng/dL, or Free T4 level: ≥1.7 ng/dL
- Presence of neck pain or Elevated ESR > ULN for age
Hashimoto’s thyroiditis with hypothyroidism (HT) cohort 4
- ≥18 years of age
- TSH > 4.2 mIU/L (normal TSH acceptable if patient is already on levothyroxine)
- TPO antibodies >9 IU/L or ULN for the assay used or US pattern, cytology or pathology consistent with HT
- History of RAI therapy or external radiation to thyroid;
- History of thyroid cancer
Graves’ orbitopathy (GO) cohort 5
- ≥18 years of age
- Presence of eye manifestations for GO; active (CAS≥3)
- History of autoimmune thyroid disease
Euthyroid Graves’ orbitopathy (EGO) cohort 6
- Same as GO – this is basically a subgroup of GO that is euthyroid (preferred those that have never been hyper- or hypothyroid)
- Normal TSH cascade
Healthy volunteers cohort 7
Inactive Graves’ Orbitopathy (IGO) cohort 8
- ≥18 years of age
- Presence of eye manifestations for GO with inactive disease (CAS<3)
- History of autoimmune thyroid disease
Exclusion Criteria:
Graves’ disease (GD) cohort 1
- Prior treatment with thyroidectomy or radioiodine or concurrent treatment with anti-thyroid drugs.
- Subjects with Graves’ orbitopathy
Painless thyroiditis (PT) cohort 2
- Exposure to iodinated contrast within 4 weeks
- Neck pain
Subacute thyroiditis (SA) cohort 3
- Exposure to iodinated contrast within 4 weeks
Hashimoto’s thyroiditis with hypothyroidism (HT) cohort 4
- History of RAI therapy or external radiation to thyroid;
- History of thyroid cancer
Graves’ orbitopathy (GO) cohort 5
- History of radiation to orbits
- Immunomodulatory therapy (exception: patients that received oral steroids more than 4 weeks prior to enrollment are allowed in the study).
- Orbital surgery
Euthyroid Graves’ orbitopathy (EGO) cohort 6
- History of radiation to orbits;
- Immunomodulatory therapy (exception: patients that received oral steroids more than 4 weeks prior to enrollment are allowed in the study).
- Orbital surgery
- Prior therapy with thyroidectomy, radioactive iodine or anti-thyroid drugs
Healthy volunteers cohort 7
- Personal history of thyroid disease
- Use of medications known to affect thyroid function
- FNA of thyroid nodule results other than benign
- Current or prior use of thyroid hormone replacement
Inactive Graves’ Orbitopathy (IGO) cohort 8
- History of radiation to orbits
- Immunomodulatory therapy (exception: patients that received oral steroids more than 4 weeks prior to enrollment are allowed in the study).
- Orbital surgery